Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.
Humans
Male
Netherton Syndrome
/ immunology
Female
Pneumococcal Vaccines
/ immunology
Adult
Cross-Sectional Studies
Vaccines, Conjugate
/ immunology
COVID-19
/ immunology
SARS-CoV-2
/ immunology
COVID-19 Vaccines
/ immunology
Retrospective Studies
Haemophilus Vaccines
/ immunology
Antibodies, Viral
/ blood
Middle Aged
mRNA Vaccines
/ immunology
Immunogenicity, Vaccine
Young Adult
Vaccination
T-Lymphocytes
/ immunology
Immunization, Secondary
SPINK5
COVID-19
Immunodeficiency
Netherton syndrome
Vaccination response
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
23
11
2023
accepted:
28
10
2024
medline:
31
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency. Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls. None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls. Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations.
Sections du résumé
BACKGROUND
BACKGROUND
Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency.
METHODS
METHODS
Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls.
RESULTS
RESULTS
None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls.
CONCLUSIONS
CONCLUSIONS
Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations.
Identifiants
pubmed: 39476295
doi: 10.1007/s10875-024-01828-0
pii: 10.1007/s10875-024-01828-0
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
COVID-19 Vaccines
0
Haemophilus Vaccines
0
Antibodies, Viral
0
mRNA Vaccines
0
23-valent pneumococcal capsular polysaccharide vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2024. The Author(s).
Références
Orphanet. Netherton syndrome 2008. https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=938&Disease_Disease_Search_diseaseType=ORPHA&Disease_Disease_Search_diseaseGroup=634&Disease(s)/group%20of%20diseases=Comel-Nethertonsyndrome&title=Comel-Netherton-syndrome&search=Disease_Search_Simple .
Ragamin A, Nouwen AEM, Dalm V, van Mierlo MMF, Lincke CR, Pasmans S. Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series. Dermatology. 2022:1–9.
Bitoun E, Micheloni A, Lamant L, Bonnart C, Tartaglia-Polcini A, Cobbold C, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet. 2003;12(19):2417–30.
doi: 10.1093/hmg/ddg247
pubmed: 12915442
Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141–2.
doi: 10.1038/75977
pubmed: 10835624
Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013;351(2):289–300.
doi: 10.1007/s00441-013-1558-1
pubmed: 23344365
Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9):3607–19.
doi: 10.1091/mbc.e07-02-0124
pubmed: 17596512
pmcid: 1951746
Fortugno P, Bresciani A, Paolini C, Pazzagli C, El Hachem M, D’Alessio M, et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol. 2011;131(11):2223–32.
doi: 10.1038/jid.2011.174
pubmed: 21697885
Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem. 2005;386(11):1173–84.
doi: 10.1515/BC.2005.134
pubmed: 16307483
Descargues P, Deraison C, Prost C, Fraitag S, Mazereeuw-Hautier J, D’Alessio M, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol. 2006;126(7):1622–32.
doi: 10.1038/sj.jid.5700284
pubmed: 16628198
Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–47.
doi: 10.1084/jem.20082242
pubmed: 19414552
pmcid: 2715042
Furio L, Hovnanian A. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol Chem. 2014;395(9):945–58.
doi: 10.1515/hsz-2014-0137
pubmed: 25153381
Bitoun E, Chavanas S, Irvine AD, Lonie L, Bodemer C, Paradisi M, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol. 2002;118(2):352–61.
doi: 10.1046/j.1523-1747.2002.01603.x
pubmed: 11841556
Stuvel K, Heeringa JJ, Dalm V, Meijers RWJ, van Hoffen E, Gerritsen SAM, et al. Comel-Netherton syndrome: a local skin barrier defect in the absence of an underlying systemic immunodeficiency. Allergy. 2020;75(7):1710–20.
doi: 10.1111/all.14197
pubmed: 31975472
Sarri CA, Roussaki-Schulze A, Vasilopoulos Y, Zafiriou E, Patsatsi A, Stamatis C, et al. Netherton Syndrome: a genotype-phenotype review. Mol Diagn Ther. 2017;21(2):137–52.
doi: 10.1007/s40291-016-0243-y
pubmed: 27905021
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
doi: 10.1007/s10875-022-01289-3
pubmed: 35748970
pmcid: 9244088
Eranko E, Ilander M, Tuomiranta M, Makitie A, Lassila T, Kreutzman A, et al. Immune cell phenotype and functional defects in Netherton syndrome. Orphanet J Rare Dis. 2018;13(1):213.
doi: 10.1186/s13023-018-0956-6
pubmed: 30477583
pmcid: 6258305
Renner ED, Hartl D, Rylaarsdam S, Young ML, Monaco-Shawver L, Kleiner G, et al. Comel-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol. 2009;124(3):536–43.
doi: 10.1016/j.jaci.2009.06.009
pubmed: 19683336
pmcid: 3685174
Hannula-Jouppi K, Laasanen SL, Ilander M, Furio L, Tuomiranta M, Marttila R, et al. Intrafamily and Interfamilial Phenotype Variation and immature immunity in patients with Netherton Syndrome and Finnish SPINK5 founder mutation. JAMA Dermatol. 2016;152(4):435–42.
doi: 10.1001/jamadermatol.2015.5827
pubmed: 26865388
Smith DL, Smith JG, Wong SW, deShazo RD. Netherton’s syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol. 1995;95(1 Pt 1):116–23.
doi: 10.1016/S0091-6749(95)70159-1
pubmed: 7822652
Stryk S, Siegfried EC, Knutsen AP. Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Pediatr Dermatol. 1999;16(1):19–22.
doi: 10.1046/j.1525-1470.1999.99005.x
pubmed: 10027993
Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1–24.
doi: 10.1016/j.jaci.2012.07.002
pubmed: 22935624
Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–65.
doi: 10.1016/j.jaci.2016.07.019
pubmed: 27554821
6 Warning Signs for PID in Adults. European Society for Immunodeficiencies; [ https://esid.org/Working-Parties/Clinical-Working-Party/Resources/6-Warning-Signs-for-PID-in-Adults
Borgers H, Meyts I, De Boeck K, Raes M, Sauer K, Proesmans M, et al. Fold-increase in antibody titer upon vaccination with pneumococcal unconjugated polysaccharide vaccine. Clin Immunol. 2012;145(2):136–8.
doi: 10.1016/j.clim.2012.08.010
pubmed: 23026475
Schaballie H, Bosch B, Schrijvers R, Proesmans M, De Boeck K, Boon MN, et al. Fifth percentile cutoff values for Antipneumococcal Polysaccharide and Anti-salmonella typhi vi IgG describe a normal polysaccharide response. Front Immunol. 2017;8:546.
doi: 10.3389/fimmu.2017.00546
pubmed: 28553290
pmcid: 5427071
Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010;134(2):198–205.
doi: 10.1016/j.clim.2009.10.006
pubmed: 19914139
Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149(6):1034–5.
doi: 10.1093/infdis/149.6.1034
pubmed: 6610714
GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7(69):eabo2202.
doi: 10.1126/sciimmunol.abo2202
pubmed: 35113647
Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 2021;6(59).
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, et al. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis. 2023;23(8):901–13.
doi: 10.1016/S1473-3099(23)00140-8
pubmed: 37088096
Gomez EV, Bishop JL, Jackson K, Muram TM, Phillips D. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in healthy participants. BioDrugs. 2017;31(6):545–54.
doi: 10.1007/s40259-017-0249-y
pubmed: 29116597
pmcid: 5696443
Vihta KD, Pouwels KB, Peto TEA, Pritchard E, Eyre DW, House T, et al. Symptoms and severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positivity in the General Population in the United Kingdom. Clin Infect Dis. 2022;75(1):e329–37.
doi: 10.1093/cid/ciab945
pubmed: 34748629
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol. 2022;149(6):1949–57.
doi: 10.1016/j.jaci.2022.04.002
pubmed: 35421449
pmcid: 8996444
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.
doi: 10.1038/s41591-021-01377-8
pubmed: 34002089
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, et al. Immune responses 6 months after mRNA-1273 COVID-19 vaccination and the Effect of a third vaccination in patients with inborn errors of immunity. J Clin Immunol. 2023;43(6):1104–17.
doi: 10.1007/s10875-023-01514-7
pubmed: 37231290
pmcid: 10212732
Faber J, Fonseca LM. How sample size influences research outcomes. Dent Press J Orthod. 2014;19(4):27–9.
doi: 10.1590/2176-9451.19.4.027-029.ebo
Indrayan A, Mishra A. The importance of small samples in medical research. J Postgrad Med. 2021;67(4):219–23.
doi: 10.4103/jpgm.JPGM_230_21
pubmed: 34845889
pmcid: 8706541